普通食品谎称能治病，又一网红品牌栽了

Core Viewpoint - The article highlights a case of false advertising involving Meihui Biotechnology (Shanghai) Co., Ltd., which was fined for misleading claims about its product "TaiKong 30" during a live-streaming event [1][10]. Group 1: Company Overview - Meihui Biotechnology is the exclusive e-commerce distributor of the "Junxiaobao" product line, which includes the controversial "TaiKong 30" [3]. - The "Junxiaobao" brand is operated by Shanghai Junxiaobao Health Technology Co., Ltd., a subsidiary of Shanghai Chenguan Health Technology Group, founded by Tu Zuitao in 2002 [18][19]. Group 2: Product and Marketing Strategy - The "TaiKong 30" product was marketed as a powerful solution for women's health, claiming to improve private area conditions within 10 days and alleviate various gynecological issues [6][9]. - The brand has utilized a robust marketing strategy involving celebrity endorsements and collaborations with top live-streaming hosts, achieving significant sales figures, such as over 50.6 million yuan in GMV from a collaboration with the Guo Yue couple [27][28]. Group 3: Regulatory Actions and Consequences - The Shanghai market supervision authority initiated an investigation into Meihui Biotechnology for false advertising, leading to a fine of 30,000 yuan [1][11]. - The investigation revealed that the "TaiKong 30" product is merely a regular food item without any therapeutic claims, contradicting the promotional statements made during live streams [9][10]. Group 4: Market Performance and Implications - Despite the regulatory issues, Junxiaobao reported a remarkable 406.51% year-on-year increase in online sales during the 2024 618 shopping festival, ranking fourth in the health supplement sector [30]. - The incident serves as a cautionary tale for the industry, emphasizing the risks of prioritizing sales over compliance and product integrity, which could lead to regulatory scrutiny and market exclusion [33].